Refining indications for the use of mitomycin C using a randomized controlled trial with an animal model

Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 4, 2007, Pages 653-657

  Shvidler, Joseph ^a   Bothwell, Nici E ^a   Cable, Benjamin ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON DIOXIDE LASER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INDICATION; FERRET; GASTROINTESTINAL SURGERY; HISTOPATHOLOGY; INFLAMMATION; NONHUMAN; RANDOMIZATION; RESTENOSIS; SCORING SYSTEM; SIMULATION; SUBGLOTTIC STENOSIS; WOUND HEALING;

ANIMALS; DISEASE MODELS, ANIMAL; FERRETS; LARYNGOSTENOSIS; MITOMYCIN; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 34047098320     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2006.10.037     Document Type: Article

References (22)

1. O'Reilly R.C., Goldman S.A., Widner S.A., et al. Creating a stable tympanic membrane perforation using mitomycin C. Otolaryngol Head Neck Surg 124 (2001) 40-45
2. Chung J.H., Cosenza M.J., Rahbar R., et al. Mitomycin C for the prevention of adhesion formation after endoscopic sinus surgery: a randomized, controlled study. Otolaryngol Head Neck Surg 126 (2002) 468-474
3. Rahbar R., Valdez T.A., and Shapshay S.M. Preliminary results of intraoperative mitomycin-C in the treatment and prevention of glottic and subglottic stenosis. J Voice 14 (2000) 282-286
4. Unal M. The successful management of congenital laryngeal web with endoscopic lysis and topical mitomycin-C. Int J Pediatr Otorhinolaryngol 68 (2004) 231-235
5. Annino Jr. D.J., and Goguen L.A. Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction. Laryngoscope 113 (2003) 1499-1502
6. Hartnick C.J., Hartley B.E., Lacy P.D., et al. Topical mitomycin application after laryngotracheal reconstruction: a randomized, double-blind, placebo-controlled trial. Arch Otolaryngol Head Neck Surg 127 (2001) 1260-1264
7. Tomasz M., and Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 76 (1997) 73-87
8. Abbas T., Olivier M., Lopez J., et al. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem 277 (2002) 40513-40519
9. Cummings J., Spanswick V.J., Tomasz M., et al. Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development. Biochem Pharmacol 56 (1998) 405-414
10. Eliashar R., Eliachar I., Esclamado R., et al. Can topical mitomycin prevent laryngotracheal stenosis?. Laryngoscope 109 (1999) 1594-1600
11. Cable B.B., Pazos G.A., Brietzke S.E., et al. Topical mitomycin therapy in the pediatric airway: state of the art. Oper Tech Otolaryngol 13 (2002) 57-64
12. Caron R.M., and Hamilton J.W. Preferential effects of the chemotherapeutic DNA crosslinking agent mitomycin C on inducible gene expression in vivo. Environ Mol Mutagen 25 (1995) 4-11
13. Khaw P.T., Sherwood M.B., Doyle J.W., et al. Intraoperative and post operative treatment with 5-fluorouracil and mitomycin-C: long term effects in vivo on subconjunctival and scleral fibroblasts. Int Ophthalmol 16 (1992) 381-385
14. Hu D., Sires B.S., Tong D.C., et al. Effect of brief exposure to mitomycin C on cultured human nasal mucosa fibroblasts. Ophthal Plast Reconstr Surg 16 (2000) 119-125
15. Jang C.H., Song C.H., and Pak S.C. Effect of exposure to mitomycin C on cultured tympanic membrane fibroblasts. Int J Pediatr Otorhinolaryngol 67 (2003) 173-176
16. Anduze A.L. Pterygium surgery with mitomycin-C: ten-year results. Ophthalmic Surg Lasers 32 (2001) 341-345
17. Rodriguez J.A., Ferrari C., and Hernandez G.A. Intraoperative application of topical mitomycin C 0.05% for pterygium surgery. Bol Asoc Med P R 96 (2004) 100-102
18. Eliashar R., Gross M., Maly B., et al. Mitomycin does not prevent laryngotracheal repeat stenosis after endoscopic dilation surgery: an animal study. Laryngoscope 114 (2004) 743-746
19. Correa A.J., Reinisch L., Sanders D.L., et al. Inhibition of subglottic stenosis with mitomycin-C in the canine model. Ann Otol Rhinol Laryngol 108 (1999) 1053-1060
20. Nakamura H., Siddiqui S.S., Shen X., et al. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 10 (2004) 703-711
21. Mead A.L., Wong T.T., Cordeiro M.F., et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 44 (2003) 3394-3401
22. Friese M.A., Wischhusen J., Wick W., et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64 (2004) 7596-7603